13 Novembre 2008 | Report Research | Area Principale Cell therapeutics (Update 7) Cell Therapeutics has announced that it achieved the primary efficacy endpoint of its phase III EXTEND trial of pixantrone (BBR 2778) for patients with advanced, relapsed aggressive non-Hodgkin’s lymphoma (NHL) based on a preliminary intent to treat efficacy analysis.
